

I hereby certify that this correspondence is being deposited with the United States Postal Service express mail in an envelope addressed to:  
Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on December 11, 2003

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By

Chiapti Appeling

Attorney Docket No. 1012-010001US  
Client Ref. No. SJK/BP5868062

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

RADEMACHER, Thomas William, et al.

Application No.:

Filed:

For: IPG ANTAGONISTS FOR THE TREATMENT OF CONDITIONS INVOLVING MAST CELLS, BASOPHILS AND EOSINOPHILS

Examiner: Amy M. Decloux

Art Unit: 1644

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97 and § 1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO-1449 form are being called to the attention of the Examiner to make of record references cited in parent application USSN 09/601,971 filed August 9, 2000. Pursuant to 37 CFR § 1.98(d), copies of references cited in parent application USSN 09/601,971 filed August 9, 2000 are not provided. However the applicants will gladly provide fresh copies of any references requested by the Examiner.

It is respectfully requested that the cited information on the attached 1449 form(s) be expressly considered during the prosecution of this application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

RADEMACHER, Thomas William, et al.

Application No.:

Page 2

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Jonathan Alan Quine, J.D., Ph.D.  
Reg. No. 41,261

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.  
P.O. BOX 458  
Alameda, CA 94501  
(510) 337-7871  
Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A-B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		<b>Complete if Known</b>	
		Application Number	<b>Not yet known</b>
		Filing Date	<b>December 11, 2003</b>
		First Named Inventor	<b>RADEMACHER, Thomas William</b>
		Group Art Unit	<b>1644</b>
		Examiner Name	<b>Amy M. Decloux</b>
		Attorney Docket Number	<b>1012-010001US</b>
		Date Submitted	<b>December 11, 2003</b>

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	1	5,418,147		Huang et al.	05-23-1995

<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		

<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	2	MIKAYAMA et al., Molecular Cloning and Functional Expression of a cDNA Encoding Glycosylation-Inhibiting Factor, PNAS, 90:10056-10060 (1993).			
	3	COLMAN et al., Research in Immunology, 145(1): 33-36 (1994).			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# COPY FROM PARENT

(Modified) PTO/SB/08A-B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		Application Number	<del>09/001,071</del> Not yet known
		Filing Date	<del>March 29, 1999</del> December 11, 2003
		First Named Inventor	RADEMACHER, Thomas William
		Group Art Unit	1644
		Examiner Name	Amy M. D. cl ux
		Attorney Docket Number	<del>1012-010000US</del> 1012-D10001US
		Date Submitted	April 10, 2003 December 11, 2003

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	AA	<b>Caro et al., (1997)</b> "Isolation and Partial Characterization of Insulin-Mimetic Inositol Phosphoglycans from Human Liver" <i>Biochem. Molec. Med.</i> , 61:214-228.			
	AB	<b>Davitz et al., (1989)</b> "Purification of a Glycosyl-Phosphatidylinositol-specific Phospholipase D from Human Plasma" <i>J. Biol. Chem.</i> , 264:13760-13764			
	AC	<b>Fisher et al., (1987)</b> "Platelet-Basophil Interactions: Clinical Correlates" <i>J. Allergy Clin. Immunol.</i> , 79:196, Abstract 288.			
	AD	<b>Gilfillan et al., (1992)</b> "Conservation of Signal Transduction Mechanisms via the Human Fc,Rla After Transfection into a Rat Mast Cell Line, RBL 2H3" <i>J. Immunol.</i> , 149(7):2445-2451			
	AE	<b>Gitomer and Tipton, (1986)</b> "Purification and kinetic properties of ox brain histamine N-methyltransferase" <i>Biochem. J.</i> , 233:669-676			
	AF	<b>Jaramillo et al., (1994)</b> "An Effective Strategy for the Synthesis of 6-O-(2-Amino-2-deoxy-.alpha.-D-glucopyranosyl)-D-chiro- and -D-myo-inositol 1-Phosphate Related to Putative Insulin Mimetics" <i>J. Org. Chem.</i> , 59:3135-3141			
	AG	<b>Kuna et al., (1993)</b> "Characterization of the Human Basophil Response to Cytokines, Growth Factors, and Histamine Releasing Factors of the Intercrine/Chemokine Family" <i>J. Immunol.</i> , 150(50):1932-1943			
	AH	<b>Kunara et al., (1995)</b> "Tissue Specific Release of Inositol Phosphoglycans" In: <i>Biopolymers and Bioproducts: Structure, Function and Applications</i> , Eds. Svasti et al., 301-306			
	AI	<b>Lichtenstein, (1988)</b> "Histamine-releasing factors and IgE heterogeneity" <i>J. Allergy Clin. Immunol.</i> , 91(5:1):814-820			
	AJ	<b>Liu et al., (1986)</b> "Human Lung Macrophage-Derived Histamine-Releasing Activity is Due to IgE-Dependent Factors" <i>J. Immunol.</i> , 136:2588			
	AK	<b>MacDonald et al., (1995)</b> "Molecular Identification of an IgE-Dependent Histamine-Releasing Factor" <i>Science</i> , 269:688-690			
	AL	<b>Sampson et al., (1989)</b> "Spontaneous Release of Histamine from Basophils and Histamine-Releasing Factor in Patients with Atopic Dermatitis and Food Hypersensitivity" <i>New England Journal of Medicine</i> , 321(4):228-232			
Examiner Signature			Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/601,974 <i>Not Yet Known</i>
		Filing Date	March 29, 1999 <i>December 11, 2003</i>
		First Named Inventor	RADEMACHER, Thomas William
		Group Art Unit	1644
		Examiner Name	Amy M. D. cl ux
		Attorney Docket Number	1012-010000US-1012-010001US
		Date Submitted	April 18, 2003 <i>December, 11, 2003</i>

	AM	<b>Sim et al.</b> , (1992) "Measurement of histamine-releasing factor activity in individual nasal washings: Relationship with atopy, basophil response, and membrane-bound IgE" <u>J. Allergy Clin. Immunol.</u> , 89(6):1157-1165	
	AN	<b>Solley et al.</b> , (1976) "The Late Phase of the Immediate Wheal and Flare Skin Reaction" <u>J. Clin. Invest.</u> , 58(2):408	
	AO	<b>Sutton and Gould</b> , (1993) "The human IgE network" <u>Nature</u> , 366:421-428	
	AP	<b>Verbourg et al.</b> , (1983) "A New Radioenzymatic Assay for Histamine Using Purified Histamine N-Methyltransferase" <u>Life Sciences</u> , 32:2855-2867	
	AQ	<b>Yasuda et al.</b> , (1995) "Expression and function of fibronectin binding integrins on rat mast cells" <u>Int. Immunol.</u> , 7:251-258	
	AR	<b>Zapata et al.</b> , (1994) "Synthesis and investigation of the possible insulin-like activity of 1D-4-O- and 1D-6-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl)-myo-inositol 1-phosphate and 1D-6-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl)-myo-inositol 1,2-(cyclic phosphate)". <u>Carbohydrate Res.</u> , 264:21-31	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## COPY FROM PAPER

(Modified) PTO/SB/08A-B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/601,071- <i>Not yet known</i>
		Filing Date	March 29, 1999- <i>December 11, 2005</i>
		First Named Inventor	RADEMACHER, Thomas William
		Group Art Unit	1614
		Examiner Name	Unassigned Amy Decloux
		Attorney Docket Number	1012-1000US-1012-D1000X US

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	AA	WO	96/29425		University College London	09-26-1996		
	AB	WO	98/10791		Hoeft Rademacher Ltd.	03-19-1998		
	AC	WO	98/11116		Hoeft Rademacher Ltd.	03-19-1998		
	AD	WO	98/11117		Hoeft Rademacher Ltd.	03-19-1998		
	AE	WO	98/11435		Hoeft Rademacher Ltd.	03-19-1998		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T
	AF	Rademacher, T.W. et al., "Inositolphosphoglycan second messengers" Brazilian Journal Med. Biol. Res. 27:327-341 (1994).			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.